Why the study?
Pulmonary arterial hypertension leads to right ventricular failure and decreased exercise tolerance, prompting an assessment of ECG parameters reflecting right heart hypertrophy as predictors of clinical status.
Do electrocardiographic parameters reflecting right heart hypertrophy correlate with clinical status and disease severity in patients with pulmonary arterial hypertension?
Observational (n=26)
No
Do electrocardiographic parameters reflecting right heart hypertrophy correlate with clinical status and disease severity in patients with pulmonary arterial hypertension?
Standard 12-lead ECG parameters, particularly the RV Sokolow-Lyon index and QRS duration, correlate significantly with hemodynamic severity and exercise capacity in PAH, offering an accessible tool for risk stratification.
Background: Pulmonary arterial hypertension (PAH) is a rare disease leading to right ventricular (RV) failure and manifests in decreasing exercise tolerance. Our study aimed to assess the usefulness of electrocardiographic parameters reflecting right heart hypertrophy as predictors of clinical status in PAH. Methods: The retrospective analysis included 26 patients, mean 49 ± 17 years of age, diagnosed with PAH, and eligible to undergo cardiopulmonary exercise test (CPET). The relations between ECG values and parameters obtained in procedures such as six-minute walk test (6-MWT), echocardiography, right heart catheterization (RHC), and CPET were analyzed. Results: P-wave amplitude in lead II correlated positively with CPET parameter of respiratory response: minute ventilation to carbon dioxide production slope (VE/VCO 2 slope; r = 0.436, p = 0.029) and echocardiographic estimated RA pressure (RAP; r = 0.504, p = 0.02). RV Sokolow-Lyon index (RVSLI) positively correlated with echocardiographic parameters reflecting RV function, overload, and afterload–tricuspid regurgitation pressure gradient (TRPG; r = 0.788, p < 0.001), RV free wall thickness ( r = 0.738, p < 0.001), and mean pulmonary arterial pressure (mPAP ECHO ; r = 0.62, p = 0.0016), respectively, as well as VE/VCO 2 slope ( r = 0.593, p = 0.001) and mPAP assessed directly in RHC (mPAP RHC ; r = 0.469, p = 0.0497). R-wave in lead aVR correlated positively with TRPG ( r = 0.719, p < 0.001), mPAP ECHO ( r = 0.446, p = 0.033), and several hemodynamic criteria of PAH diagnosis: positively with mPAP RHC ( r = 0.505, p = 0.033) and pulmonary vascular resistance ( r = 0.554, p = 0.026) and negatively with pulmonary capillary wedge pressure ( r = −0.646, p = 0.004). QRS duration correlated positively with estimated RAP ( r = 0.589, p = 0.004), vena cava inferior diameter ( r = 0.506, p = 0.016), and RA area ( r = 0.679, p = 0.002) and negatively with parameters of exercise capacity: peak VO 2 ( r = −0.486, p = 0.012), CPET maximum load ( r = − 0.439, p = 0.025), and 6-MWT distance ( r = −0.430, p = 0.046). ROC curves to detect intermediate/high 1-year mortality risk (based on ESC criteria) indicate RVSLI (cut-off point: 1.57 mV, AUC: 0.771) and QRS duration (cut-off points: 0.09 s, AUC: 703 and 0.1 s, AUC: 0.759) as relevant predictors. Conclusion: Electrocardiography appears to be an important and underappreciated tool in PAH assessment. ECG corresponds with clinical parameters reflecting PAH severity.
No takes yet. Share an insight, caveat, or question.
Michalski et al. (2022) conducted an observational in Pulmonary arterial hypertension (n=26). Electrocardiographic parameters (e.g., RVSLI, QRS duration) was evaluated on Correlation between ECG parameters and clinical/hemodynamic markers of PAH severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: